electroCore (NASDAQ:ECOR) Given New $10.00 Price Target at JMP Securities

electroCore (NASDAQ:ECOR) had its price objective decreased by JMP Securities to $10.00 in a research report report published on Thursday morning, The Fly reports. JMP Securities currently has a positive rating on the stock.

Several other analysts have also commented on ECOR. Zacks Investment Research lowered shares of electroCore from a buy rating to a hold rating in a research report on Tuesday. Noble Financial reaffirmed a buy rating and set a $11.00 price target on shares of electroCore in a research report on Thursday. ValuEngine raised shares of electroCore from a hold rating to a buy rating in a research report on Thursday, August 1st. BTIG Research reaffirmed a hold rating on shares of electroCore in a research report on Wednesday. Finally, Cantor Fitzgerald lowered shares of electroCore from an overweight rating to a neutral rating and reduced their price target for the company from $19.00 to $9.00 in a research report on Thursday, May 30th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $13.50.

ECOR traded up $0.01 during trading on Thursday, reaching $1.52. The company’s stock had a trading volume of 52,820 shares, compared to its average volume of 126,562. The company has a quick ratio of 10.07, a current ratio of 10.74 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $1.55 and a two-hundred day simple moving average of $4.56. electroCore has a 1 year low of $1.23 and a 1 year high of $17.99. The company has a market cap of $46.22 million, a price-to-earnings ratio of -1.28 and a beta of 2.84.

electroCore (NASDAQ:ECOR) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.04. electroCore had a negative net margin of 4,450.22% and a negative return on equity of 81.85%. The business had revenue of $0.62 million for the quarter. As a group, equities analysts forecast that electroCore will post -1.57 EPS for the current fiscal year.

In other news, Director Thomas J. Errico purchased 21,000 shares of electroCore stock in a transaction dated Thursday, June 6th. The shares were purchased at an average price of $1.77 per share, with a total value of $37,170.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 43.78% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in ECOR. BlackRock Inc. grew its stake in shares of electroCore by 1.8% during the fourth quarter. BlackRock Inc. now owns 280,813 shares of the company’s stock valued at $1,758,000 after buying an additional 4,934 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of electroCore during the fourth quarter valued at approximately $108,000. Northern Trust Corp grew its stake in shares of electroCore by 7.7% during the fourth quarter. Northern Trust Corp now owns 66,397 shares of the company’s stock valued at $415,000 after buying an additional 4,724 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of electroCore by 38.1% during the fourth quarter. Geode Capital Management LLC now owns 45,632 shares of the company’s stock valued at $285,000 after buying an additional 12,578 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of electroCore during the fourth quarter valued at approximately $85,000. 15.36% of the stock is currently owned by hedge funds and other institutional investors.

electroCore Company Profile

electroCore, Inc, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Read More: Systematic Risk and Investors

The Fly

Analyst Recommendations for electroCore (NASDAQ:ECOR)

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.